Cytokinetics (CYTK)
(Delayed Data from NSDQ)
$59.36 USD
+1.47 (2.54%)
Updated May 14, 2024 04:00 PM ET
After-Market: $59.37 +0.01 (0.02%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
Brokerage Reports
0 items in cart
Cytokinetics, Incorporated [CYTK]
Reports for Purchase
Showing records 301 - 305 ( 305 total )
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Initiates CK-357 Peripheral Artery Disease and Claudication Phase IIa Study
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Q1:10 Earnings and Update to CK-357 Studies and omecamtiv mecarbil Studies
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
CYTK Announces Statistically Significant Results from the CK-20173537 Phase I Trial
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G